Why focal chondral defects need a different conversation to arthritis

Being told you have cartilage damage does not automatically mean you need a repair procedure — and understanding why depends on a distinction that shapes every treatment decision that follows.

Cartilage damage falls broadly into two categories. Generalised, diffuse thinning across a joint compartment is the territory of osteoarthritis, where preservation or eventual replacement tends to dominate the conversation. A focal chondral defect is something different: a localised, crater-like lesion in an otherwise largely intact joint surface. The surrounding cartilage may be healthy, the joint alignment may be good, and the patient is often younger than a typical arthritis candidate. It is this group — focal defect, structurally sound joint — where surgical repair and regenerative strategies come into their own.

Severity is commonly mapped using the ICRS or Outerbridge grading system, which runs from Grade I (superficial softening or fissuring) to Grade IV (full-thickness loss down to subchondral bone). Repair and regenerative options become most relevant at Grade III–IV, where the defect penetrates the full depth of the cartilage layer and spontaneous healing is essentially absent — articular cartilage is avascular, aneural, and alymphatic, conferring extremely limited regenerative capacity on its own.

Defect size is perhaps the single most recurring variable in this field. Lesions under 2 cm² have historically been addressed by marrow-stimulation techniques. Those between 2 cm² and 6 cm² are the principal territory for cell-based implantation. Beyond 6 cm², or where underlying bone is involved, larger reconstructive options come into play. These size thresholds recur throughout the evidence and reappear at each step of the treatment decision.

One important caveat for readers with kneecap-side damage: patellofemoral defects consistently produce worse outcomes across all repair techniques than lesions on the femoral condyle, a pattern observed even in well-designed comparative cohorts. This does not mean repair is futile in that location, but expectations should be calibrated accordingly from the outset.

For younger patients with focal defects, the treatment ladder runs from symptom management and biologic support through to cartilage restoration, with joint replacement reserved for cases where the joint is too far compromised. The comparison this article examines sits in the restoration tier: established surgical repair procedures on one side, and emerging stem cell and MSC-based strategies on the other.

What established cartilage repair procedures show in clinical trials

The clearest comparative data in this field comes from a 2022 systematic review of six randomised controlled trials (five Level I) matching autologous chondrocyte implantation (ACI) — in which cartilage cells are harvested from the patient, cultured in a laboratory, and re-implanted into the defect — against microfracture. Treatment failure for ACI and its scaffold-based refinement, matrix-induced autologous chondrocyte implantation (MACI, where cultured cells are delivered pre-seeded on a collagen membrane), ran from 0 to 1.8%; microfracture failure reached 2.5–8.3% over the same two-to-six-year window. Patients treated with ACI showed significantly greater improvement across multiple Knee injury and Osteoarthritis Outcome Score (KOOS) subscales and on the Tegner activity scale, which measures return to sporting and daily function.

For anyone weighing the commitment of a two-stage procedure, longer-term MACI data is reassuring. A 2024 systematic review of 168 patients found maintained functional gains across 10–17 years, a 9.0% all-cause reoperation rate, and only 7.4% progressing to total knee replacement.

A 2024 meta-analysis of 47 studies and 1,993 patients placed four established procedures on broadly equal footing at around five years: ACI, MACI, osteochondral autograft transfer (OATS, also called mosaicplasty — which moves a plug of bone and cartilage from a lower-load area of the same knee), and osteochondral allograft (OCA, using donor tissue rather than the patient's own). All four met the minimum clinically important difference (MCID) and patient acceptable symptom state (PASS) thresholds for pain and function. A six-year cohort of 148 patients separately found ACI and OCA produce equivalent knee scores for femoral condyle lesions without underlying bone loss; OCA is the more natural route when defects are large or involve bone that autograft tissue cannot adequately address.

OATS suits smaller lesions of roughly 1–2 cm² (mosaic configurations may extend to 4 cm²), with donor-site discomfort at the harvest location as a meaningful trade-off to discuss at consultation. Microfracture, by contrast, is now considered a historical first-line option: the failure-rate gap and inferior repair-tissue quality documented in RCT-level evidence have prompted its declining use. Where marrow stimulation is still performed, autologous matrix-induced chondrogenesis (AMIC — microfracture augmented with a scaffold membrane) may improve cartilage quality on MRI without requiring a second surgical stage, though clinical score gains over microfracture alone remain modest at around two years.

Stem cell and MSC therapies: what the evidence actually shows

The biological logic behind mesenchymal stem cell (MSC) approaches is genuinely compelling. Unlike autologous chondrocyte implantation, MSC-based therapies require no cartilage biopsy, avoiding donor-site morbidity and the two-stage wait for cell culture. MSCs can also be expanded to larger numbers than autologous chondrocytes — an attractive property when treating bigger defects. It is not hard to see why researchers have pursued this direction.

The difficulty lies in translating that logic into durable tissue. MSCs expanded outside the body tend to lose stable chondrogenic identity, producing fibrocartilage rather than the hyaline-like matrix that withstands long-term joint loading. This remains the central unresolved biological challenge, and it has a direct consequence for the clinical evidence: without consistently hyaline repair tissue, head-to-head trials against MACI or osteochondral allograft — the reference-standard cell-based procedures — have not yet been conducted at scale. No large RCTs exist. That is not a minor caveat; it is the principal gap in the field.

One animal study warrants specific mention precisely because it challenges a common assumption. In a minipig model, adding MSC extracellular vesicles to bone marrow stimulation actually produced worse cartilage repair than bone marrow stimulation alone — lower matrix staining, poorer cell morphology, and a collagen I–to–collagen II ratio skewing toward fibrocartilage. Subchondral bone mineralisation improved, but the cartilage surface did not. This is a single preclinical study, and the finding has not been replicated in further animal or human work, so it cannot be read as disqualifying. What it does show is that MSC-derived signals interact with the repair environment in ways that are not yet predictable — more biological activity does not straightforwardly mean better cartilage.

In clinical practice, bone marrow aspirate concentrate (BMAC) — a cell-rich concentrate drawn from the patient's own iliac crest — shows consistent short-to-mid-term improvements in KOOS and IKDC scores when combined with scaffold matrices. Published evidence suggests outcomes are meaningfully better in patients under 50–60 years of age and for defects under 6 cm², where MSC viability in the concentrate tends to be higher. BMAC represents the most clinically mature MSC-adjacent option currently available, though long-term follow-up data comparable to MACI's 10–17-year series does not yet exist.

Particulated autologous cartilage with PRP and high-density ACI are worth watching as next-stage developments — preclinical collagen profiling for the former is promising — but neither has established itself as a clinical standard.

Augmenting microfracture: scaffolds, biologics, and where the evidence falls short

Patients and GPs often ask whether adding a scaffold or biologic agent to microfracture delivers meaningfully better results. The most direct answer comes from a meta-analysis of 14 studies and 744 patients: at approximately 27 months, augmented microfracture showed no statistically significant advantage over isolated microfracture on the three most-used patient-reported measures — VAS pain, IKDC function, and WOMAC. Augmentation did, however, improve MOCART scores, the MRI-based measure of repair tissue fill and integrity. Better imaging appearance without a matching clinical score gain is a meaningful distinction when patients have seen encouraging scan results but wonder whether their symptoms have genuinely improved.

The BioCartilage ECM scaffold combined with microfracture produces a more encouraging short-term picture. A 48-patient, eight-centre prospective study reported 90% of patients achieving MCID and 85% reaching PASS at two years, with only 2.1% experiencing treatment failure — reasonable numbers, though two-year follow-up cannot establish the durability seen in MACI's ten-to-seventeen-year series.

Cell-free scaffolds used in isolation show stable improvements in pain and function to three years and beyond across 23 studies and 521 patients, but evidence quality is predominantly observational and direct comparisons against cell-based strategies remain limited.

AMIC — a single-stage approach layering a scaffold membrane over the marrow-stimulation step — occupies a practical middle ground when standard microfracture is insufficient but full two-stage ACI or MACI is not yet warranted or accessible.

None of these augmentation strategies resolves the subchondral bone plate damage that repeated or failed marrow stimulation can cause — the clinical problem increasingly directing the field towards cell-based procedures for larger or mechanically demanding defects.

Matching technique to patient: defect size, age, and other key variables

Defect size is usually the first variable a specialist considers, and it does the most to narrow the field. For lesions under 2 cm², single-stage procedures — OATS or AMIC — are typically appropriate. Between 2 and 6 cm², ACI, MACI, and osteochondral allograft transplantation (OCA) are all viable; the published evidence does not cleanly separate them at this size range, and clinical judgement carries more weight here than at other thresholds. Above 6 cm², OCA or combined reconstructive approaches become the dominant options — the volume of tissue required exceeds what autograft or cell implantation alone can reliably restore.

Age modifies those starting points in a meaningful way. Cell-based and MSC-adjacent therapies show consistently stronger outcomes in patients under 50–60 years, where progenitor cell viability — in harvested chondrocytes and in bone marrow aspirate concentrate — tends to be higher. Published evidence also suggests outcomes are better for defects under 6 cm² on this basis. Beyond the 50–60 threshold, durability data become thinner and joint replacement moves into the realistic medium-term horizon, shifting the risk–benefit conversation rather than foreclosing repair altogether.

Where the defect sits in the knee matters independently of size. Femoral condyle lesions carry better functional prognoses across all techniques than patellofemoral defects — a consistent pattern across the literature and consistent with the cohort data discussed in earlier sections. For patients with patellofemoral pathology, this is an honest expectation-setter before surgery rather than a reason to decline it.

Bone involvement tips the decision further. When the subchondral layer has been lost or significantly damaged, OCA becomes preferable because it restores bone and cartilage simultaneously; a scaffold or cell implant placed on a deficient bone bed is unlikely to achieve durable fixation.

Prior microfracture is a subtler but clinically important variable. Marrow stimulation can damage the subchondral plate, and evidence suggests this compromises ACI outcomes when patients seek escalation after a first failed procedure — making treatment history a routine part of any specialist assessment.

Concomitant mechanical problems — malalignment, ligament laxity, meniscal deficiency — are evaluated alongside the cartilage defect itself. Unaddressed loading issues tend to accelerate graft failure regardless of technique, so alignment correction or meniscal reconstruction may need to accompany or precede cartilage repair.

Finding a knee cartilage specialist in the UK

The evidence does point in some clear directions for patients at the decision stage. Where a focal femoral condyle defect falls between 2 and 6 cm² with intact subchondral bone and no prior marrow stimulation, ACI and MACI rest on substantially stronger long-term data than any current MSC or stem cell strategy. Bone involvement shifts the conversation towards osteochondral allograft. Stem cell and MSC approaches remain genuinely promising but have not yet been tested against established cell-based procedures in large-scale head-to-head human trials — a gap that matters when choosing between them.

Translating those signals into a personalised plan — accounting for defect grade, location, prior procedures, and activity goals — is a task for imaging and specialist assessment, not an article. Search MSK lists knee cartilage specialists across the UK who offer cartilage repair and restoration procedures; filter by region and specialty to find one near you.